<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">Direct-acting oral anticoagulants (DOACs) can also be considered in the treatment of thromboembolism in COVID-19 infection. However, drug interactions between DOAC and antiviral treatments, as well as dosing concerns in the setting of changing kidney function, need to be considered before prescribing these drugs [
 <xref ref-type="bibr" rid="CR79">79</xref>]. Asakura et al. have proposed the use of nafamostat, a synthetic serine protease inhibitor, as a short-acting anticoagulant with antiviral properties, along with heparin, in COVID patients; more data are required regarding the efficacy of this agent [
 <xref ref-type="bibr" rid="CR80">80</xref>]. A study has shown an increased incidence of VTE even in anticoagulated patients, but the small sample size and retrospective nature are two limitations of that study [
 <xref ref-type="bibr" rid="CR81">81</xref>]. Recently published clinical data have suggested that systemic anticoagulation may be associated with positive outcomes among patients hospitalized with COVID-19, but that study has some limitations, including its observational nature and unobserved confounding factors [
 <xref ref-type="bibr" rid="CR82">82</xref>].
</p>
